Immunogenicity and effectiveness of virosomal adjuvanted vaccines against influenza: A brief review of their utility in the elderly population

Journal of Preventive Medicine and Hygiene

Volumn 52, Issue 3, 2011, Pages 116-119

  Zamparo, E ^a   Little, D'Anna ^a  

^a Department of Prevention   (Italy)

Author keywords

Immunogenicity; Influenza; Virosomal adjuvanted vaccine

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM POTASSIUM SULFATE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MIFAMURTIDE; OVALBUMIN; PNEUMOCOCCUS VACCINE; VIROSOME; VIROSOME VACCINE; VIRUS SIALIDASE;

ADULT; AGED; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COST BENEFIT ANALYSIS; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GERIATRIC PATIENT; HUMAN; HUMORAL IMMUNITY; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; IMMUNOSTIMULATION; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; MAJOR HISTOCOMPATIBILITY COMPLEX; MORBIDITY; MORTALITY; REVIEW; SCLERODERMA; SEASONAL INFLUENZA; SENESCENCE; SEROCONVERSION; TH1 CELL; UNSPECIFIED SIDE EFFECT; VIRUS IMMUNITY; VIRUS STRAIN;

AGED; HUMANS; IMMUNOGENETIC PROCESSES; INFLUENZA VACCINES; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE; VACCINES, VIROSOME;

EID: 80052926622     PISSN: 11212233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. World Health Organisation Europe. Surveillance and Epidemiology. 2011. http://www.euro.who.int/en/what-we-do/health-topics/communicable-diseases/ influenza (accessed June 6, 2011).
2. Organisation for Economic Co-operation and Development (OECD). Influenza Vaccination for Older People. In: OECD, Health at a Glance: Europe 2010. OECD Publishing. http://dx.doi.org/10.1787/health-glance-2010-en (accessed June 6, 2011).
3. Fiore AE, Uyeki TM, Broder K, et al.; Centers for Disease Control and Prevention (CDC). Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010;59:1-62.
4. Durando P, Iudici R, Alicino C, et al. Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine. Hum Vaccin 2011;7:29-40.
5. Gasparini R, Lucioni C, Lai P, et al. Influenza surveillance in the Italian region of Liguria in the winter of 1999-2000 by general practitioners and paediatricians: socio-economic implications. J Prev Med Hyg 2001;42:83-6.
6. Gasparini R, Lucioni C, Lai P, et al. Valutazione benefici-costi della vaccinazione antinfluenzale negli anziani in Liguria. Pharmacoeconomics Italian Research Articles 2003;5(Suppl 1):23-30. (Pubitemid 36553336)
7. De Bruijn IA, Nauta J, Gerez L, et al. Virosomal influenza vaccine: a safe and effective influenza vaccine with high efficacy in elderly and subjects with low pre-vaccination antibody titers. Virus Res 2004;103:139-45. (Pubitemid 38659591)
8. De Bruijn IA, Nauta J, Gerez L, et al. The virosomal influenza vaccine Invivac: immunogenicity and tolerability compared to an adjuvanted influenza Vaccine. Vaccine 2006;24:6629-31.
9. Herzog C, Hartmann K, Künzi V, et al. Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine. Vaccine 2009;27:4381-7.
10. Calcagnile S, Zuccotti GV. The virosomal adjuvanted influenza vaccine. Expert Opin Biol Ther 2010;10:191-200.
11. Dupuis M, Murphy TJ, Higgins D, et al. Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell Immunol 1998;186:18-27. (Pubitemid 28285344)
12. Brunner R, Jensen-Jarolim E, Pali-Schöll I. The ABC of clinical and experimental adjuvants - a brief overview. Immunol Lett 2010;128:29-35.
13. The European Agency for the Evaluation of Medicinal Products (EMA). Guideline on adjuvants in vaccines for human use. Committee for medicinal products for human use (CHMP) 2005. (pub. No. EMEA/CHMP/VEG/134716/2004).
14. Wilschut J. Influenza vaccines: the virosomal concept. Immunol Lett 2009;122:118-21.
15. Moser C, Metcalfe IC, Viret JF. Virosomal adjuvanted antigen delivery systems. Expert Rev Vaccines 2003;2:189-96. (Pubitemid 36559924)
16. Bungener L, Huckriede A, De Mare A, et al. Virosomal-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. Vaccine 2005;23:1232-41. (Pubitemid 40126526)
17. Daemen T, De Mare A, Bungener L, et al. Virosomals for antigen and DNA delivery. Adv Drug Deliv Rev 2005;57:451-63.
18. Huckriede A, Bungener L, Stegmann T, et al. The virosomal concept for influenza vaccines. Vaccine 2005;23(Suppl 1):S26-38.
19. Cryz SJ, Que JU, Glück R. A virosomal vaccine antigen delivery system does not stimulate an antiphospholipid antibody response in humans. Vaccine 1996;14:1381-3. (Pubitemid 27008201)
20. Kürsteiner O, Moser C, Lazar H, et al. Inflexal V - the influenza vaccine with the lowest ovalbumin content. Vaccine 2006;24:6632-5. (Pubitemid 46107152)
21. Esposito S, Gasparini C, Martelli A, et al. Safe administration of an inactivated virosomal adjuvanted influenza vaccine in asthmatic children with egg allergy. Vaccine 2008;26:4664-8.
22. Fedson DS. Measuring protection: efficacy versus effectiveness. Dev Biol Stand 1998;95:195-201.
23. Brydak LB, Machala M. Humoral immune response to influenza vaccination in patients from high risk groups. Drugs 2000;60:35-53. (Pubitemid 30601315)
24. Plotkin SA Correlates of Vaccine-Induced Immunity. Clin Infect Dis 2008;47:401-9.
25. European Agency for the Evaluation of Medicinal Products (EMEA). Note for guidance on harmonisation of requirements for influenza vaccines. Committee for proprietary medicinal products 1997. (Pub. No. CPMP/BWP/214/96.).
26. Kanra G, Marchisio P, Feiterna-Sperling C, et al. Comparison of immunogenicity and tolerability of a virosomal-adjuvanted and a split influenza vaccine in children. Pediatr Infect Dis J 2004;23:300-6. (Pubitemid 38508880)
27. Esposito S, Marchisio P, Ansaldi F, et al. A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal- adjuvanted influenza vaccine administered to unprimed children aged 6-35 months. Vaccine 2010;28:6137-44.
28. Salleras L, Dominguez A, Pumarola T, et al. Effectiveness of virosomal subunit influenza vaccine in preventing influenza-related illnesses and its social and economic consequences in children aged 3-14 years: a prospective cohort study. Vaccine 2006;24:6638-42. (Pubitemid 46107153)
29. Zuccotti GV, Cucchi C, Sala D, et al. Immunogenicity and safety of a virosomal influenza vaccine in HIV-infected children. Acta Paediatr 2002;91:486-7.
30. Amendola A, Boschini A, Colzani D, et al. Influenza vaccination of HIV-1-positive and HIV-1-negative former intravenous drug users. J Med Virol 2001;65:644-8. (Pubitemid 33135090)
31. Zuccotti GV, Scaramuzza A, Riboni S, et al. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus. Vaccine 2009;27:5357-62.
32. Zuccotti GV, Amendola A, Viganò A, et al. Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma. Vaccine 2007;25:6692-8. (Pubitemid 47332732)
33. Schaad UB, Bühlmann R, Burger R, et al. Comparison of immunogenicity and safety of a virosome influenza vaccine with those of a subunit influenza vaccine in pediatric patients with cystic fibrosis. Antimicrob Agents Chemother 2000;44:1163-7. (Pubitemid 30228289)
34. Gaeta GB, Pariani E, Amendola A, et al. Influenza vaccination in patients with cirrhosis and liver transplant recipients. Vaccine 2009;27:3373-5.
35. Setti M, Fenoglio D, Ansaldi F, et al. Flu vaccination with a virosomal vaccine does not affect clinical course and immunological parameters in scleroderma patients. Vaccine 2009;27:3367-72.
36. Glück R, Mischler R, Finkel B, et al. Immunogenicity of new virosomal influenza vaccine in elderly people. Lancet 1994;344:160-3. (Pubitemid 24218879)
37. Conne P, Gauthey L, Vernet P, et al. Immunogenicity of trivalent subunit versus virosomal-formulated influenza vaccines in geriatric patients. Vaccine 1997;15:1675-9. (Pubitemid 27445747)
38. De Bruijn IA, Nauta J, Cramer WC, et al. Clinical experience with inactivated, virosomal influenza vaccine. Vaccine 2005;23(Suppl 1):S39-49.
39. Zamparo M, Conversano M, Mastronuzzi L, et al. Comparison of the safety and immunogenicity of two adjuvanted influenza vaccines in elderly subjects. Poster presentation at the First International Conference on Influenza Vaccines, Lisboa, Portugal, 24-26 May 2004.
40. Ruf BR, Colberg K, Frick M, et al. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosomal- based subunit vaccine in elderly. Infection 2004;32:191-8. (Pubitemid 39070597)
41. Pregliasco F, Mensi C, Serpilli W, et al. Immunogenicity and safety of three commercial influenza vaccines in institutionalized elderly. Aging 2001;13:38-43. (Pubitemid 32241877)
42. Consonni S, Sandrini C, Segato E, et al. Tolerability and efficacy od anti-influenza vaccination alone and associated with antipneumococcal vaccination in an elderly ambulatory population and adherence to the vaccination campaign. J Prev Med Hyg 2004;45:45-50. (Pubitemid 40546755)
43. Pregliasco F, Giardini G, Sandrini MC, et al. Protective efficacy of Inflexal V in elderly. Prooceding on Scientific Symposium on Vaccination against Influenza. Kemi, Finland, 21-24 March 2002.
44. Gasparini R, Lucioni C, Mazzi S, et al. Vaccino adiuvato vs. vaccino tradizionale nella strategia antiinfluenzale: una valutazione farmacoeconomica. In: Pharmacoeconomics Issues in Vaccines. Milano: Adis International Limited 2002.